Dianthus Therapeutics, Inc.
DNTH
Rang în acțiuni
#4062
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Preț acțiune
$71.45
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$4.00B
Schimbare (1 zi)
-4.13%
Schimbare (1 an)
100.42%
Țară
US
Tranzacționează Dianthus Therapeutics, Inc. (DNTH)
Categorie
Healthcare
EPS pentru Dianthus Therapeutics, Inc. (DNTH)
EPS la data de June 2026 TTM: $-0.13
Conform celor mai recente rapoarte financiare și prețului acțiunilor Dianthus Therapeutics, Inc., EPS-ul actual al companiei (TTM) este $-0.13. La sfârșitul anului 2023, compania avea un EPS de $-8.45 o creștere față de EPS-ului din 2022, care a fost de $-7.60.
Istoricul EPS pentru Dianthus Therapeutics, Inc. din 2016 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-0.13 | -94.90% |
| 2024 | $-2.55 | -69.82% |
| 2023 | $-8.45 | 11.18% |
| 2022 | $-7.60 | 98.95% |
| 2021 | $-3.82 | -86.01% |
| 2020 | $-27.30 | -17.72% |
| 2019 | $-33.18 | 20.13% |
| 2018 | $-27.62 | 72.09% |
| 2017 | $-16.05 | 275.88% |
| 2016 | $-4.27 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -13,423.08% |
US
|
|
| $-7.98 | 6,038.46% |
US
|
|
| $-5.29 | 3,969.23% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -21,438.46% |
NL
|
